Wall Street Zen Upgrades Caribou Biosciences (NASDAQ:CRBU) to Hold

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $8.50.

Caribou Biosciences Stock Performance

NASDAQ CRBU opened at $1.36 on Friday. The company has a market capitalization of $126.48 million, a P/E ratio of -0.84 and a beta of 2.48. Caribou Biosciences has a one year low of $0.66 and a one year high of $3.00. The stock has a 50 day moving average price of $1.08 and a 200-day moving average price of $1.19.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). Caribou Biosciences had a negative net margin of 1,490.84% and a negative return on equity of 55.70%. The business had revenue of $2.35 million during the quarter, compared to analyst estimates of $1.48 million. As a group, equities analysts predict that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Trading of Caribou Biosciences

Institutional investors have recently bought and sold shares of the stock. Centric Wealth Management bought a new stake in shares of Caribou Biosciences in the 4th quarter worth about $27,000. Cerity Partners LLC lifted its stake in Caribou Biosciences by 163.6% in the first quarter. Cerity Partners LLC now owns 40,722 shares of the company's stock worth $37,000 after purchasing an additional 25,271 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after purchasing an additional 21,416 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after purchasing an additional 9,148 shares during the last quarter. Finally, Diametric Capital LP bought a new stake in Caribou Biosciences in the fourth quarter worth about $42,000. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.